METTL6: A Potential Drug Target and Biomarker (G131965)

Target Name: METTL6

NCBI ID: G131965

METTL6

METTL6: A Potential Drug Target and Biomarker

METTL6, or microRNA-6 (miRNA-6), is a non-coding RNA molecule that has been shown to play a critical role in various cellular processes, including cell growth, differentiation, and programmed cell death (apoptosis). METTL6 has also has been linked to various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As such, it has potential as a drug target or biomarker in a variety of settings.

The discovery and characterization of METTL6 comes from a team of researchers led by Dr. Yasmina Boudjemaa at the University of Montreal, who reported the identification and characterization of the microRNA in 2008. Since then, studies have continued to unravel the functions and mechanisms of METTL6 in various cellular processes, as well as its potential as a drug target or biomarker.

One of the key functions of METTL6 is its role in cell apoptosis. Apoptosis, a natural and regulated process of cell death, is crucial for the development and maintenance of tissues and organs, and is often associated with diseases such as cancer, neurodegenerative diseases, and trauma. METTL6 has been shown to play a critical role in the regulation of apoptosis, by promoting the production and degradation of pro-apoptotic microRNAs (miRNAs) and inhibiting the production of anti-apoptotic microRNAs.

In addition to its role in apoptosis, METTL6 has also been shown to be involved in various other cellular processes, including cell growth, differentiation, and cell-cell signaling. For example, studies have shown that METTL6 can promote the production and differentiation of neural stem cells, and that it plays a role in regulating the movement of cells along the blood vessels.

METTL6 has also been linked to various diseases and disorders, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that METTL6 is often overexpressed in various types of cancer, and that it can contribute to the development and progression of these diseases. In addition, METTL6 has also been linked to various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease, and has been shown to play a role in the development and progression of these conditions.

Given the potential involvement of METTL6 in various cellular processes and the association with various diseases, it has significant potential as a drug target or biomarker. Studies have shown that METTL6 can be effectively targeted with small molecules, such as inhibitors of its translation or degradation, leading to potential therapeutic approaches for various diseases. For example, researchers have shown that inhibiting METTL6 can effectively treat neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, by reducing the production of pro-inflammatory miRNAs.

In conclusion, METTL6 is a microRNA molecule that has been shown to play a critical role in various cellular processes, including cell growth, differentiation, and apoptosis. Its potential as a drug target or biomarker for various diseases makes it an attractive target for further research and development. Further studies are needed to fully understand the functions and mechanisms of METTL6, as well as its potential as a therapeutic approach for various diseases.

Protein Name: Methyltransferase 6, Methylcytidine

Functions: S-adenosyl-L-methionine-dependent methyltransferase that mediates N(3)-methylcytidine modification of residue 32 of the tRNA anticodon loop of tRNA(Ser), including tRNA(Ser)(UGA) and tRNA(Ser)(GCU) (PubMed:32923617, PubMed:34922197, PubMed:34268557, PubMed:34862464). Interaction with SARS1/SerRS is required for N(3)-methylcytidine methylation (PubMed:34268557)

The "METTL6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about METTL6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets